Real-world evaluation of compliance and preference in Alzheimer’s disease treatment: an observational study in Taiwan

PURPOSE: Among the medications approved for Alzheimer’s disease (AD), rivastigmine is the only one available as transdermal patch. The aim of this study was to evaluate compliance and caregivers’ preference with oral and transdermal (rivastigmine) monotherapy in patients with mild-to-moderate AD fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Tzu-Hsien, Wang, Wen-Fu, Yip, Bak-Sau, Yang, Yu-Wan, Peng, Giia-Sheun, Tsai, Shih-Jei, Liao, Yi-Chu, Pai, Ming-Chyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821393/
https://www.ncbi.nlm.nih.gov/pubmed/27099476
http://dx.doi.org/10.2147/PPA.S95271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821393/
https://www.ncbi.nlm.nih.gov/pubmed/27099476
http://dx.doi.org/10.2147/PPA.S95271

Ejemplares similares